Loading viewer...
investor_presentation
Format: PDF investor_presentation
MorphoSys AG updates on its platform for antibody and peptide-based therapeutics, highlighting 40+ academic and pharma collaborations with over 100 ongoing programs and 28 clinical candidates. The company emphasizes its innovative antibody platform, strong balance sheet, and lucrative milestone and royalty potential from its partner strategy.
investor_presentation
20 Pages
investor_presentation
45 Pages
Archaea Energy
IFF DuPont Nutrition Biosciences merger 2019
investor_presentationinvestor_presentation
25 Pages
IFF (International Flavors & Fragrances)
